FDA Drug Approvals, Board Elections, and Agreed and Completed Acquisitions - Analyst Notes on Quintiles, ICON, Alere, WuXi and Novadaq

NEW YORK, May 16, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Quintiles Transnational Holdings Inc. (NYSE: Q), ICON plc (NASDAQ: ICLR), Alere Inc. (NYSE: ALR), WuXi PharmaTech (Cayman) Inc. (NYSE: WX) and Novadaq Technologies Inc. (NASDAQ: NVDQ). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2535-100free.

Quintiles Transnational Holdings Inc. Analyst Notes
On May 12, 2014, Quintiles Transnational Holdings Inc. (Quintiles) announced that it has signed an agreement to acquire Encore Health Resources (Encore). Encore is a leader in the health-information analytics and technology services industry focused on healthcare providers. "Today's announcement signifies the increasing importance of leveraging EHR and real-world information to inform our customers and improve their probability of success," said Tom Pike, CEO. "Encore has significant EHR expertise, strong relationships with many large U.S. provider networks and academic medical centers as well as experienced consultants, proven tools, and methodologies. It will be a key strategic addition for our business that will extend our services suite and allow us to work with Encore to strengthen its provider-focused solutions." According to the Company, the transaction is expected to close later in Q2 2014, following which Encore will join Quintiles' Integrated Healthcare Services segment and be known as "Encore, A Quintiles Company." The full analyst notes on Quintiles are available to download free of charge at:

http://www.analystsreview.com/2535-Q-16May2014.pdf

ICON plc Analyst Notes
On May 8, 2014, ICON plc (ICON) announced the completion of its previously announced acquisition of Aptiv Solutions (Aptiv). "Aptiv's adaptive trial capabilities, combined with our existing technology platforms, such as ICONIK and Firecrest, will further differentiate our services and help our customers take time and cost out of the development process," commented Dr. Nuala Murphy, President, ICON Clinical Research Services. "Their presence in Japan and medical device capabilities will also broaden our offerings in these markets." Aptiv is a company focused on the design and execution of adaptive clinical trials for pharmaceutical and biotech customers. The full analyst notes on ICON are available to download free of charge at:

http://www.analystsreview.com/2535-ICLR-16May2014.pdf

Alere Inc. Analyst Notes
On May 5, 2014, Alere Inc. (Alere) announced that the separation of CEO and Chairman roles, under which the Board unanimously elected Gregg J. Powers as Chairman of the Board of Alere while Ron Zwanziger will continue as President, CEO and a member of the Board. Further, the Company also announced that Alere is undertaking a comprehensive review of its strategy and operations, which is to aid the Company in finding opportunities to enhance shareholder value. The Board also intends to select and engage an international consulting organization to assist it with this process in the near future. The full analyst notes on Alere are available to download free of charge at:

http://www.analystsreview.com/2535-ALR-16May2014.pdf

WuXi PharmaTech (Cayman) Inc. Analyst Notes
On May 5, 2014, WuXi PharmaTech (WuXi) and TaiMed Biologics announced the FDA approval of the first batch of the ibalizumab (TMB-355) drug substance and sterile drug product for ongoing treatment of patients under investigator-sponsored IND's. Dr. Ge Li, Chairman and CEO of WuXi PharmaTech commented, "WuXi is proud to serve as a gateway for developing novel biologics in China. Our integrated biologics discovery, development, manufacturing and testing service platform provides our customers with a seamless solution to bring their biologics products to the market globally and in China." According to the Company, this is the first reported FDA approval of a sterile biologics product manufactured in China for use under a U.S. IND, which represents an important milestone of WuXi's investment to expedite global development of innovative biologics. The full analyst notes on WuXi are available to download free of charge at:

http://www.analystsreview.com/2535-WX-16May2014.pdf

Novadaq Technologies Inc. Analyst Notes
On May 12, 2014, Novadaq Technologies Inc. (Novadaq) announced that after satisfying all closing conditions, it has completed the acquisition of Aïmago SA ("Aïmago"). Founded in 2008, Aïmago was previously a privately held medical imaging company, which was a spin off from Ecole Polytechnique Fédérale de Lausanne ("EPFL") - a Switzerland based academic and research institution. Aïmago will now continue as a fully owned Novadaq subsidiary. The full analyst notes on Novadaq are available to download free of charge at:

http://www.analystsreview.com/2535-NVDQ-16May2014.pdf

About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.

===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

http://www.analystsreview.com/

SOURCE Analysts Review